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BACKGROUND: We analysed 10-year survival data in 19411 women aged 50–64 years diagnosed with invasive breast cancer in the
West Midlands region of the United Kingdom. The aim was to estimate the survival advantage seen in cases that were screen
detected compared with those diagnosed symptomatically and attribute this to shifts in prognostic variables or survival differences
specific to prognostic categories.
METHODS: We studied tumour size, histological grade and the Nottingham Prognostic Index in very narrow categories and investigated
the distribution of these prognostic factors within screen-detected and symptomatic tumours. We also adjusted for lead time bias.
RESULTS: The unadjusted 10-year breast cancer survival in screen-detected cases was 85.5% and in symptomatic cases 62.8%; after
adjustment for lead time bias, survival in the screen-detected cases was 79.3%. Within narrow categories of prognostic variables,
survival differences were small, indicating that the majority of the survival advantage of screen detection is due to differences in the
distributions of size and node status.
CONCLUSION: Our results suggested that a combination of lead time with size and node status in 10 categories explained almost all
(97%) of the survival advantage. Only a small proportion remained to be explained by biological differences, manifested as length bias
or overdiagnosis.
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Breast cancer screening with mammography is known to reduce
mortality from the disease (Smith et al, 2004) and although there is
some dissent (Gøtzsche et al, 2009), the majority opinion is that
mammographic screening is effective (Vainio, 2002). The major
mechanism of this mortality reduction is the diagnosis of disease
at an early stage, while it is likely to be successfully treatable
(Taba ´r et al, 1985; Smith et al, 2004).
In recent years, there has been interest in the extent to which
screen-detected breast cancer differs from symptomatic disease in
biological terms (Collett et al, 2005; Wishart et al, 2008). Survival
studies have indicated that the majority of the survival benefit can
be attributed to smaller size and a lesser rate of node involvement
at presentation (Wishart et al, 2008). Biological variables such as
HER-2 status apparently account for o10% of the difference in
prognosis between screen-detected and symptomatic cancers
(Dawson et al, 2009). Around 30% of the difference remains to
be explained (Wishart et al, 2008; Dawson et al, 2009).
It is also of interest to study survival differences in narrow
prognostic categories, to ascertain whether the difference can be
better explained by more minute categorisation of factors such as
tumour size, and whether the survival advantage of screen-
detected tumours is more marked in higher risk or lower risk
tumours. It is also desirable to take lead time into account in
explaining survival differences.
In this paper, we investigate the proportion of the survival
difference between screen-detected and symptomatic tumours that
can be explained by tumour size, a combination of tumour size
and node status, histological grade and the Nottingham Prognostic
Index (NPI), which takes into account all three prognostic factors.
In addition, we estimate the difference that can be explained by
lead time, the additional observation time added to the survival as
a result of early detection by screening.
We also use a method, described by Bashir and Este `ve (2000),
for partitioning the variation in survival between the two modes of
breast cancer detection (screening or symptomatic) with respect to
(1) the distribution of prognostic factors by detection mode and
(2) differences in survival specific to prognostic factor status in
narrow categories. In this study, we used 19411 invasive breast
tumours diagnosed in women aged 50–64 years recorded by the
West Midlands Cancer Intelligence Unit. The size of the remaining
survival differences, between screen-detected and symptomatic
tumours after taking into account lead time and the difference in
pathological prognostic factors illustrates the scope of survival
differences attributable to length bias and overdiagnosis. Length
bias in the context of screening is the tendency of screening to
detect preferentially more slow-growing tumours, which therefore
have better prognosis. Overdiagnosis is the extreme form of length
bias whereby screening detects some tumours, which would never
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shave been diagnosed in the host’s lifetime had the screening not
taken place.
MATERIALS AND METHODS
In collaboration with the NHS Breast Screening Programme, the
West Midlands Cancer Intelligence Unit aims to determine the
screening histories of all women diagnosed with breast cancer in
the West Midlands, UK. Screening histories for 19411 women aged
between 50 and 64 years with invasive breast tumours diagnosed
between 1988 and 2004; 11674 (60.1%) diagnosed symptomatically
and 7737 (39.9%) screen detected are included in this study. We
studied the survival difference between symptomatic and screen-
detected tumours in relation to tumour size, grade, nodal status
and the NPI. The latter is a validated prognostic tool based on
tumour size, grade and lymph node status (Todd et al, 1987). It is
frequently categorised into five prognostic groups (Lee and Ellis,
2008): excellent (NPIo2.41), good (2.41pNPIo3.41), moderate
1 (3.41pNPIo4.41), moderate 2 (4.41pNPIo5.41) and poor
(NPIX5.41). Note that the number of cases vary among analyses,
due to different numbers with missing data on size, node status
and grade. We also considered socioeconomic status as measured
by the area-based Townsend score.
Categorical variables were compared between symptomatic and
screen-detected tumours using the w
2-test, and continuous
variables using the Wilcoxon test (Wilcoxon, 1945). For survival
analysis, we first examined the difference in 10-year Kaplan–Meier
survival (Kaplan and Meier, 1958) in five size categories between
symptomatic and screen-detected tumours. We then estimated the
expected overall survival for the symptomatic cases if they had had
the same size distribution as the screen-detected cases, using the
method of Bashir and Este `ve (2000). This yielded an estimate of
the proportion of the survival difference attributable to the more
favourable size distribution of screen-detected cancers, the
complementary proportion attributable to size-specific survival
differences between the two detection modes.
The analysis was performed with and without adjustment for
lead time. We repeated this analysis for size categorised into 10
classes, for a combination of tumour size and node status, for
histological grade and for the NPI, divided into 10 prognostic
groups. We adjusted for lead time bias using the method of Duffy
et al (2008), who estimated the additional time of observation, due
to screening lead time, between diagnosis and either death or
censoring for each screen-detected case. They showed that for a
subject who dies of breast cancer at time t, the additional time is
on average
EðsÞ¼
1   e lt   lte lt
lð1   e ltÞ
For a subject censored at time t, the average additional time is
EðsÞ¼
1   e lt
l
where l is the rate of transition from asymptomatic to sympto-
matic disease, and is the reciprocal of the average asymptomatic
screen-detectable period. We calculated E(s) for every screen-
detected case, and subtracted this from their survival time. We
estimated l as 0.26 from the largest of the breast cancer screening
trials (Taba ´r et al, 2000). This corresponds to an average
asymptomatic screen-detectable period of 3.9 years.
With the correction for lead time, the proportion of the survival
difference accounted for by pathological prognostic factors such as
size can be considered the residual proportion attributable to size
etc, after removal of the lead time effect. The difference remaining
to be accounted for is attributable to unobserved factors, and to
length bias or overdiagnosis.
The above analysis was complemented by Cox proportional
hazards regression (Clayton and Hills, 1993), estimating the
relative hazard for screen-detected cancers unadjusted and
adjusted for pathological factors and lead time. In addition, the
Freedman statistic for the proportion of the survival difference
accounted for by the various adjustment factors was calculated
(Freedman et al, 1992).
RESULTS
Patient and tumour characteristics are shown for screen-detected
and symptomatic cases in Table 1. All variables showed significant
differences between the two detection modes. The symptomatic
cases were slightly but significantly younger and slightly but
significantly more deprived, had larger tumours, had a greater
proportion of tumours with positive nodes and had tumours with a
more severe grade. Consequently, women with symptomatic
tumours had a poorer prognosis than women with cancers
detected by screening.
Table 1 Patient characteristics by mode of detection
Mode of
detection
Screen
detected Symptomatic
Test for
difference
Total numbers 7737 11674
Townsend deprivation quintile, N (%)
Least deprived 1 2067 (26.7) 2975 (25.5) w
2 for trend¼12.32,
P¼0.002
2 1745 (22.6) 2553 (21.7)
3 1522 (19.7) 2315 (19.9)
4 1427 (18.5) 2210 (19.0)
Most deprived 5 969 (12.5) 1621 (13.9)
Unknown 7 0
Age at diagnosis
Mean (s.d.) 57.2 (4.3) 56.8 (4.4) Wilcoxon rank sum
Z¼ 5.02, Po0.001
Median (IQR) 57 (53–61) 57 (53–61)
Size of tumour
Mean (s.d.) 16.5 (10.9) 26.1 (18.8) Wilcoxon rank sum
Z¼46.65, Po0.0001
Median (IQR) 15 (10–20) 20 (15–30)
N, unknown 690 2447
Nodal status
Positive 1722 (27.0) 4395 (48.1) Pearson w
2 (1),
Po0.001
Negative 4648 (73.0) 4735 (51.9)
Not examined/
unknown
1367 2544
Histological grade
1 2045 (31.9) 1099 (12.6) w
2 (3)¼1327,
Po0.001
2 3038 (47.4) 3719 (42.7)
3 1327 (20.7) 3898 (44.7)
Unknown 1327 2958
NPI
Excellent 1320 (24.7) 521 (7.7) w
2 for trend¼1600,
Po0.001
Good 1775 (33.3) 1239 (18.4)
Moderate 1 1264 (23.7) 1744 (25.8)
Moderate 2 598 (11.2) 1657 (24.6)
Poor 381 (7.1) 1589 (23.5)
Unknown 2399 4924
Abbreviations: IQR¼interquartile range; NPI¼Nottingham Prognostic Index.
Screen-detected and symptomatic breast cancer
PC Allgood et al
1681
British Journal of Cancer (2011) 104(11), 1680–1685 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sTable 2 shows invasive breast tumours categorised into five size
groups for symptomatic and screen-detected tumours and their
10-year survival rates. The unadjusted 10-year survival for women
with screen-detected tumours compared to women with sympto-
matic tumours was better in all size groups and overall. This was
most marked in the 21–50mm size groups, and the adjustment for
lead time had the strongest attenuating effect in these groups. Note
that the overall survival difference is greater than observed within
specific size categories. This indicates that a substantial part of the
survival benefit of screen detection is due not to size-specific
differences but to shifts in tumour size associated with screen
detection. This phenomenon was also observed in subsequent
analyses described below. Overall, the absolute survival advantage
for women with screen-detected tumours was 85.9–65.3¼20.6%.
The expected overall survival in the symptomatic cases if they
had had the same size distribution as the screen detected was
calculated as
S ¼85:4 0:302 þ 76:3 0:488 þ 60:5 0:146
þ 45:1 0:051 þ 31:1 0:013 ¼ 74:6%
The proportion of the survival difference explained by the different
size distributions was therefore
74:6   65:3
85:9   65:3
¼ 0:45
That is, 45% of the survival difference between screen-detected and
symptomatic cases can be attributed to the more favourable size
distribution (using these five size categories) in the screen-
detected tumours, and 55% to differences in size-specific survival.
The overall 10-year survival of the screen-detected tumours
adjusted for lead time was 79.8%. This suggests that 30% of
the difference is due to lead time. The proportion of the
remaining survival difference attributable to the differing size
distributions was
74:6   65:3
79:8   65:3
¼ 0:64
That is, 64% of the difference in survival after adjustment for lead
time is attributable to the better size distribution of screen-
detected cases.
Survival differences were markedly changed when the tumours
were divided by size and node status simultaneously (Table 3). For
node-negative tumours, the greatest survival advantage for screen-
detected cases was in the 31–50mm size group for both
unadjusted and adjusted figures. The smallest difference was seen
in the smallest tumours where indeed a slight survival advantage
was observed for women with symptomatic tumours after
adjustment for lead time. For node-positive tumours, the greatest
survival advantage was seen in women with the smallest tumours
using either unadjusted or adjusted survival figures.
The expected survival in the symptomatic tumours if they had
had the same size and node status distribution as the screen-
detected cases was 77.0%. Unadjusted for lead time, the overall
survival of the screen-detected tumours was 85.0%. Thus, before
Table 2 10-year survival for women aged 50–64 years with symptomatic and screen-detected invasive breast tumours by size of tumour in five
categories
Screen detected
Symptomatic 10-year survival (%)
Size (mm) N (%)
10-year
survival (%) N (%)
Unadjusted for
lead time
Difference from
symptomatic
Adjusted for
lead time
Difference from
symptomatic
o11 971 (10.5) 85.4 2125 (30.2) 94.3 8.9 90.9 5.5
11o21 3688 (40.0) 76.3 3442 (48.8) 87.2 10.9 80.4 4.1
21o31 2549 (27.6) 60.5 1029 (14.6) 77.2 16.7 69.3 8.8
31o51 1426 (15.5) 45.1 358 (5.1) 63.3 18.2 53.7 8.6
51+ 593 (6.4) 31.1 93 (1.3) 41.3 10.2 38.8 7.7
Overall 9227 (100) 65.3 7047 (100) 85.9 20.6 79.8 14.5
Table 3 10-year survival for women aged 50–64 years with symptomatic and screen-detected invasive breast tumours by a combination of tumour
size and nodal status
Screen detected
Symptomatic 10-year survival (%)
Size (mm) and
node status N (%)
10-year
survival (%) N (%)
Unadjusted for
lead time
Difference from
symptomatic
Adjusted for
lead time
Difference from
symptomatic
o11, Negative 564 (7.2) 93.2 1505 (25.3) 95.1 1.9 91.5  1.7
11–20, Negative 2008 (25.7) 84.1 2178 (36.6) 91.9 7.8 84.5 0.4
21–30, Negative 1073 (13.7) 74.8 521 (8.8) 85.0 10.2 76.3 1.5
31–50, Negative 433 (5.5) 59.8 135 (2.3) 77.7 17.9 68.8 9.0
51+, Negative 116 (1.5) 46.3 28 (0.5) 56.2 9.9 54.1 7.8
o11, Positive 167 (2.1) 62.4 162 (2.7) 85.7 23.3 80.4 18.0
11o21, Positive 1089 (13.9) 62.7 769 (12.9) 73.9 11.2 62.9 0.2
21o31, Positive 1135 (14.5) 47.6 403 (6.8) 64.4 16.8 56.3 8.7
31o51, Positive 835 (10.7) 36.5 196 (3.3) 51.4 14.9 38.8 2.3
51+, Positive 393 (5.0) 26.1 55 (0.9) 32.7 6.6 29.6 3.5
Overall 7813 (100.0) 64.9 5952 (100.0) 85.0 20.1 77.4 12.5
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sadjusting for lead time, 60% of the survival advantage of screen-
detected tumours was attributable to the difference between the
joint distributions of tumour size and node status. After
adjustment for lead time, the survival difference between screen-
detected and symptomatic tumours was 12.5%, and the difference
between the survival of screen-detected cases and that expected in
the symptomatic if they had had the same size/node status
distribution as the screen detected was 77.4–77.0¼0.4%. Thus,
almost all (97%) of the remaining survival difference after
adjusting for lead time was attributable to the difference between
screen-detected and symptomatic tumours in terms of size and
node status.
Table 4 shows invasive breast tumours categorised into
histological grade for symptomatic and screen-detected tumours
and their 10-year survival rates. The unadjusted and adjusted
10-year survivals for the screen-detected cases compared with
the symptomatic cases was better for all grades and overall
although less after adjusting for lead time. Overall, the absolute
survival advantage for women with screen-detected tumours was
85.0–64.9¼20.1% unadjusted. The expected overall survival in the
symptomatic cases if they had had the same size distribution as the
screen detected was 71.6%. The proportion of the survival
difference explained by the different size distributions was 34%,
so 66% was due to the difference in grade-specific survival. The
overall 10-year survival of the screen-detected tumours adjusted
for lead time was 77.4%. This suggests that 37.6% of the difference
is due to lead time. The proportion of the remaining survival
difference attributable to the differing grade distributions was 0.54,
that is, 54% of the difference in survival after adjustment for lead
time is attributable to the better grade distribution of screen-
detected cases. The greatest survival advantage was seen in women
with grade 2 tumours both before and after adjustment for lead
time and the smallest difference was seen for women with grade 1
tumours.
Since size, node status and grade are correlated, the attributable
percentages are non-exclusive and cannot be combined additively.
Table 5 shows 10-year survival for symptomatic and screen-
detected cases when tumours were divided into 10 NPI categories.
Total survival for the symptomatic tumours was 66.1%, and for the
screen-detected tumours, 84.7% unadjusted, and 75.5% after
adjustment for lead time. There was a screen-detected survival
advantage for all prognostic groups when using the unadjusted
survival figures except for women in the 4.21o4.38 group where a
small survival advantage for women with symptomatic tumours
was seen. When using lead time adjusted survival figures, there
was an even larger survival advantage seen for women with
symptomatic tumours in this prognostic group. The expected
survival for symptomatic tumours if they had had the same NPI
distribution as the screen-detected cases was 79.7%. Thus, the NPI
distribution accounted for 73% of the survival difference without
adjustment for lead time and entirely accounted for the difference
after lead time adjustment.
For some of the categories, the survival in the screen-detected
tumours is poorer after lead time adjustment. This may be due to
the fact that much of the lead time is highly correlated with the
prognostic factors making up the NPI and therefore within very
minute categories of NPI there is little residual lead time, and
therefore the correction may be an overadjustment.
Table 6 shows the relative hazard for screen-detected vs
symptomatic cancers, unadjusted and adjusted for prognostic
factors, and uncorrected and corrected for lead time. The
Freedman statistics indicate that size and node status account
Table 4 10-year survival for women aged 50–64 years with symptomatic and screen-detected invasive breast tumours by histological grade of tumour
Screen detected
Symptomatic 10-year survival (%)
Grade N (%)
10-year
survival (%) N (%)
Unadjusted for
lead time
Difference from
symptomatic
Adjusted for
lead time
Difference from
symptomatic
1 1099 (12.6) 87.3 2045 (31.9) 95.1 7.8 88.9 1.6
2 3719 (42.7) 68.1 3038 (47.4) 85.6 17.5 77.8 9.7
3 3898 (44.7) 55.4 1327 (20.7) 68.5 13.1 60.5 5.1
Overall 8716 (100) 64.8 6410 (100) 85.0 20.2 77.4 12.6
Table 5 10-year survival by mode of detection for women aged 50–64 years with invasive breast tumours in 10 NPI categories
Screen detected
Symptomatic 10-year survival
NPI N (%)
10-year
survival (%) N (%)
Unadjusted for
lead time
Difference from
symptomatic
Adjusted for
lead time
Difference from
symptomatic
o2.3 299 (4.4) 94.3 997 (18.7) 96.4 2.1 94.6 0.3
2.30o3.17 415 (6.2) 88.1 706 (13.2) 96.0 7.9 87.5  0.6
3.17o3.30 392 (5.8) 88.7 766 (14.4) 95.0 6.3 88.9 0.2
3.30o3.41 654 (9.7) 85.7 626 (11.7) 91.1 5.4 82.5  3.2
3.41o4.21 749 (11.1) 74.9 576 (10.8) 85.5 10.6 75.9 1.0
4.21o4.38 654 (9.7) 80.9 524 (9.8) 78.6  2.3 62.8  18.1
4.38o4.51 808 (12.0) 71.2 352 (6.6) 74.6 3.4 69.6  1.6
4.51o5.28 826 (12.2) 59.0 257 (4.8) 70.4 11.4 60.4 1.4
5.28o5.70 961 (14.2) 48.3 325 (6.1) 55.0 6.7 38.9  9.4
X5.70 992 (14.7) 28.6 209 (3.9) 35.1 6.5 23.3  5.3
Total 6750 (100) 66.1 5338 (100) 84.7 18.6 75.5 9.4
Abbreviation: NPI¼Nottingham Prognostic Index.
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sfor 46% of the survival difference, and that correction for lead
time, size and node status account for 90% of the difference. The
NPI accounts for 67% of the difference, but together with the
correction for lead time, it accounts for 100% of the difference.
These results are consistent with those of the Bashir and Este `ve
(2000) method. The lead time corrected and NPI adjusted results
again suggest an overcorrection.
DISCUSSION
We analysed the 10-year survival data of 19411 women aged
50–64 years diagnosed with invasive breast cancers in the West
Midlands region of the United Kingdom. The availability of the
very large tumour series with detailed screening history made it
possible to divide the cancers into very narrow prognostic bands.
Our results found a strong survival advantage for women with
screen-detected tumours as seen in many studies comparing
screen-detected and symptomatic breast cancers (Wishart et al,
2008; Dawson et al, 2009; Lawrence et al, 2009). The survival
advantage was partly explained by the more favourable distribu-
tion of tumour size in narrow prognostic categories. When screen-
detected tumour survival was additionally adjusted for lead time,
the survival advantage was still evident, but smaller. When the
tumours were classified into 10 categories by size and node status,
the survival difference was almost entirely accounted for by a
combination of lead time and the more favourable size and node
status of the screen-detected cancers, with a remaining absolute
survival difference of o1%.
A strong survival advantage was also seen for women with
screen-detected tumours when adjusted for histological grade,
which was again, attenuated when adjusted for lead time.
Simultaneously adjusting for lead time and NPI, which incorpo-
rates tumour size, node status and histological grade, the survival
difference between screen-detected and symptomatic tumours was
entirely accounted for. However, one might argue that histological
grade in many cases is an innate feature of tumour biology rather
than a time-progressive attribute of the tumour, so the size–node
status adjustment might be more appropriate.
The lead time adjustment is rigorous and based on empirical
estimation of the average preclinical screen-detectable period from
a large randomised trial, estimating the average sojourn time as 3.9
years (Tabar et al, 2000). This gave an average additional
observation due to lead time of 3 years in the screen-detected
cases in our data. The method depends also on the observed
survival time, so that the lead time correction is on average smaller
for poor prognosis tumours than for tumours with favourable
prognostic attributes. This makes overcorrection unlikely,
although there may be some overcorrection within prognostic
categories defined partially by non-progressive features. This may
be the case for the NPI results, since at the very least for some
tumours the grade is an innate rather than a progressive
characteristic of the tumour. There is a wide range of sojourn
time estimates in the literature, and a shorter mean sojourn time
would give a smaller proportion of the survival difference
accountable for by lead time. However, the estimated mean
sojourn times vary by age and in this age group, 50–64 years, they
are mostly close to our estimate of 3.9 years (Paci and Duffy, 1991;
Tabar et al, 2000; Weedon-Fekjaer et al, 2005).
The conclusion up to now has been that the portion of the
survival advantage of screen-detected cancers that could not be
attributed to the prognostic factors size and node status (and
possibly grade) must be attributable to unobserved biological
covariates (Collett et al, 2005; Wishart et al, 2008). Our results
suggest that a combination of lead time with size and node status
in 10 categories explains almost all of the survival advantage. This
does not invalidate the hypothesis of further unobserved biological
differences, since biological tumour features will almost certainly
affect tumour progression rates and therefore lead time. It does,
however, suggest that only a small proportion of the survival
advantage of screen-detected cancers remains to be explained by
biological differences between screen-detected and symptomatic
tumours.
Such biological differences are likely to give rise to length bias,
the tendency of screening to detect the more slow-growing
tumours. The extreme form of length bias is overdiagnosis, the
detection by screening of cancers that would never have been
diagnosed in the host’s lifetime if screening had not taken place.
Estimates of overdiagnosis vary considerably (Biesheuvel et al,
2007). The results here do not formally estimate the overdiagnosis
rate, but the small amount of the survival benefit that remains
unattributed after correction for lead time and adjustment for
tumour size and node status would only require a small degree of
overdiagnosis (between 3% and 10%) to account for it.
In addition to the survival difference conferred by different
distributions of prognostic factors, there were notable differences
in survival within prognostic categories. Broadly, substantially
better survival was observed with screen detection for node-
negative tumours of size 21–50mm and node-positive tumours of
size p30mm. These were partly but not entirely explained by lead
time.
In conclusion, in this large tumour series, the better survival of
screen-detected breast cancers was almost entirely explained by a
combination of lead time and the improved size and node status of
screen-detected tumours.
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